Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|June 30, 2006
Bortezomib for multiple myelomaRakesh Popat, Simon Joel, Heather Oakervee, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 8, 2014
Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence methodEssam Ghazaly, Jackie Perry, Christiana Kitromilidou, et al.
Ophthalmology and Therapy|December 6, 2023
Clinical Trials and Future Outlooks of the Port Delivery System with Ranibizumab: A Narrative ReviewSimon Joel Lowater, Jakob Grauslund, Yousif Subhi, et al.
Palliative Medicine|April 19, 2003
Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related painColumba Quigley, Simon Joel, Naina Patel, et al.
Urologia Internationalis|July 14, 2007
A comparison of the platinum analogues in bladder cancer cell linesThomas Powles, Jacky Perry, Jonathan Shamash, et al.
Molecular Cancer Therapeutics|October 5, 2010
A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRPJackie Perry, Essam Ghazaly, Christiana Kitromilidou, et al.
Leukemia & Lymphoma|July 9, 2008
Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approachWai M Liu, Katherine A Scott, Jonathan Shamash, et al.
Oncogene|December 3, 2003
Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivityWai Man Liu, Thomas Powles, Jonathan Shamash, et al.
Rheumatology International|February 27, 2025
Increased retinal thickness in sarcoidosis patients with ocular system involvement visualized with optical coherence tomography: a cross-sectional studyKeld-Erik Byg, Torkell Ellingsen, Jimmi Wied, et al.
Blood|March 2, 2010
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell deathMatthew J Streetly, Lenushka Maharaj, Simon Joel, et al.
Pageof 3